期刊文献+

沙格列汀联合二甲双胍治疗2型糖尿病的临床研究 被引量:11

Study on the effect of saxagliptin combined with metformin on type 2 diabetes
在线阅读 下载PDF
导出
摘要 目的观察2型糖尿病患者使用沙格列汀联合二甲双胍治疗后血糖的控制情况及血脂、体重指数的变化。方法选择40例2型糖尿病患者,随机分为2组。联合组20例,使用沙格列汀5 mg/d+二甲双胍2 000 mg/d;对照组20例,使用二甲双胍2 000 mg/d,治疗3个月。检测治疗前后空腹血糖(FPG)、餐后2 h血糖(PPG)、HbA1c、血脂、体重指数等,观察低血糖事件及其他不良反应。结果治疗后,联合组和对照组的空腹血糖、餐后血糖和糖化血红蛋白均显著下降,两组餐后血糖比较差异有统计学意义(P<0.05),低血糖发生率比较差异无统计学意义(P>0.05),且均未见严重不良反应。结论沙格列汀联合二甲双胍可改善2型糖尿病患者的血糖控制,无严重低血糖事件及其他不良反应。 Objective To observe the effect of saxagliptin combined with metformin on blood glucose,lowdensity lipoproteinin and BMI of patients with type 2 diabetes. Methods Forty patients were randomly divided into two groups:combined treatment group(group A) and control group(group B). Patients in group A were given metformin,2 000 mg /d,patients in group B were given the same dose of metformin with group A and saxagliptin 5 mg /d.After treatment of 3 months,the change of fasting glucose(FPG),2 h postprandial glucose(PPG),glycated hemoglobin(HbA1c),cholesterol,body mass index and adverse reactions of the patients in the two groups were compared. Results The FPG,PPG,HbA1 c in group A decreased more significantly than that in group B(P〈0. 05). There was no serious adverse reaction in the two groups(P〉0. 05). Conclusion The blood glucose can be controlled in patients using saxagliptin and metformin with no serious hypoglycemia and other adverse reactions.
出处 《实用药物与临床》 CAS 2014年第10期1358-1360,共3页 Practical Pharmacy and Clinical Remedies
关键词 沙格列汀 二甲双胍 2型糖尿病 Saxagliptin Metformin Type 2 diabetes
  • 相关文献

参考文献11

  • 1Xu Y,Wang L,He J,et al.Prevalence and control of diabetes in Chinese adults[J] .JAMA,2013,310(9):948-959.
  • 2杨敏,柳洁.中国糖尿病防治现状[J].中国医学创新,2014,11(7):149-151. 被引量:64
  • 3张儒雅,陆菊明.DPP-4抑制剂在2型糖尿病治疗中的应用[J].中华内分泌代谢杂志,2011,27(1):101-104. 被引量:75
  • 4Unger RH.Alpha-and beta-cell interrelationships in health and disease[J] .Metabolism,1974,23(6):581-593.
  • 5Schofield CJ,Sutherland C.Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes[J] .Diabt Med,2012,29(8):972-979.
  • 6景斐,郑冬梅,管庆波,赵家军.肠促胰素类药物在2型糖尿病治疗中的作用及评价[J].药品评价,2013,10(13):28-31. 被引量:4
  • 7Drucker DJ.The biology of incretin hormones[J] .Cell Metab,2006,3:153-165.
  • 8Ahren B,Foley JE.The islet enhancer vidagliptin:mechanisms of improved glucose metabolism[J] .Int J Clin Pract Suppl,2008,(159):8-14.
  • 9Colagiuri S. 餐后血糖治疗指南(IDF). 2008.
  • 10中华医学会糖尿病学分会.中国2型糖尿病防治指南[M].2010.

二级参考文献74

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].高血压杂志,2004,12(6):483-486. 被引量:368
  • 2潘长玉,中国区合作调查组.中国糖尿病控制现状——指南与实践的差距 亚洲糖尿病治疗现状调查1998,2001及2003年中国区结果介绍[J].国外医学(内分泌学分册),2005,25(3):174-178. 被引量:396
  • 3潘长玉.中国2型糖尿病治疗现状与目标的差距[J].中华医学信息导报,2005,20(6):19-19. 被引量:6
  • 4Goke B.Islet cell function:alpha and beta cells-partners towards normoglycaemia.Int J Clin Pract Suppl,2008,(159):2-7.
  • 5Kim MH,Lee MK.The incretins and pancreatic beta-cells:use of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes Mellitus.Korean Diabetes J,2010,34:2-9.
  • 6Kim W,Egan JM.The role of incretins in glucose homeostasis and diabetes treatment.Pharmacol Rev,2008,60:470-512.
  • 7Neumiller JJ,Wood L,Campbell RK.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Pharmacotherapy,2010,30:463-484.
  • 8Deacon CF.Circulation and degradation of GIP and GLP-1.Horm Metab Res,2004,36:761-765.
  • 9Deacon CF,Carr RD,Holst JJ.DPP-4 inhibitor therapy:new directions in the treatment of type 2 diabetes.Front Biosci,2008,13:1780-1794.
  • 10Lankas GR,Leiting B,Roy RS,et al.Dipeptidyl peptidase Ⅳ inhibition for the treatment of type 2 diabetes:potential importance of selectivity over dipeptidyl peptidases 8 and 9.Diabetes,2005,54:2988 -2994.

共引文献147

同被引文献113

  • 1宋燕庆.二甲双胍联合沙格列汀与二甲双胍单药治疗2型糖尿病疗效比较[J].兵团医学,2013(4):18-19. 被引量:2
  • 2杨文英,纪立农,陆菊明,等.中国2型糖尿病防治指南[S].北京:北京大学医学出版社,2011.
  • 3Clement K,Viguerie N,Poitou C,et al.Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects[J].FASEB,2004,18(14):1657-1669.
  • 4Yang WY,Lu JM,Weng JP,et al.Prevalence of diabetes among men and women in China[J].N Engl J Med,2010,362(12):1090-1101.
  • 5Kahn SE,Hull RL,Utzschneider KM.Mechanisms linking obesity to insulin resistance and type 2 diabetes[J].Nature,2006,444(7121):840-846.
  • 6Harford KA,Reynolds CM,McGillicuddy FC,et al.Fats,inflammation and insulin resistance:insights to the role of maerophage and T-cell accumulation in adipose tissue[J].Proc Nutr Soc,2011,70(4):408-417.
  • 7Matarese G,Procaccini C,De Rosa V,et al.Regulatory T cells in obesity:the leptin connection[J].Cell,2010,16(6):247-256.
  • 8Hotamisligil GS.Inflammation and metabolic disorders[J].Nature,2006,444(7121):860-867.
  • 9Hundal RS,Petersen KF,Mayerson AB,et al.Mechanism by which high-dose Aspirin improves glucose metabolism in type 2 diabetes[J].J Clin Invest,2002,109(10):1321-1326.
  • 10Gao Z,Zuberi A,Quon MJ, et al.Aspirin inhibits sefine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases[J].J Biol Chem,2003,278(27):24944-24950.

引证文献11

二级引证文献113

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部